[go: up one dir, main page]

WO2007031879A3 - Lipid a analogs for treating oral and gastrointestinal mucositis - Google Patents

Lipid a analogs for treating oral and gastrointestinal mucositis Download PDF

Info

Publication number
WO2007031879A3
WO2007031879A3 PCT/IB2006/003538 IB2006003538W WO2007031879A3 WO 2007031879 A3 WO2007031879 A3 WO 2007031879A3 IB 2006003538 W IB2006003538 W IB 2006003538W WO 2007031879 A3 WO2007031879 A3 WO 2007031879A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
lipid
gastrointestinal mucositis
treating oral
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/003538
Other languages
French (fr)
Other versions
WO2007031879A2 (en
Inventor
Tetsu Kawano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Priority to AU2006290437A priority Critical patent/AU2006290437A1/en
Priority to CA002606727A priority patent/CA2606727A1/en
Priority to JP2008510678A priority patent/JP2008540510A/en
Priority to EP06831669A priority patent/EP1879597A2/en
Publication of WO2007031879A2 publication Critical patent/WO2007031879A2/en
Publication of WO2007031879A3 publication Critical patent/WO2007031879A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides methods of reducing the severity of oral and gastrointestinal mucositis, involving administration of a toll-like receptor 4 antagonist.
PCT/IB2006/003538 2005-05-13 2006-05-15 Lipid a analogs for treating oral and gastrointestinal mucositis Ceased WO2007031879A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2006290437A AU2006290437A1 (en) 2005-05-13 2006-05-15 Methods of reducing the severity of oral and gastrointestinal mucositis
CA002606727A CA2606727A1 (en) 2005-05-13 2006-05-15 Lipid a analogs for treating oral and gastrointestinal mucositis
JP2008510678A JP2008540510A (en) 2005-05-13 2006-05-15 Methods for relieving symptoms of oral mucositis and gastrointestinal mucositis
EP06831669A EP1879597A2 (en) 2005-05-13 2006-05-15 Lipid a analogs for treating oral and gastrointestinal mucositis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68073305P 2005-05-13 2005-05-13
US60/680,733 2005-05-13

Publications (2)

Publication Number Publication Date
WO2007031879A2 WO2007031879A2 (en) 2007-03-22
WO2007031879A3 true WO2007031879A3 (en) 2007-10-04

Family

ID=37772612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/003538 Ceased WO2007031879A2 (en) 2005-05-13 2006-05-15 Lipid a analogs for treating oral and gastrointestinal mucositis

Country Status (7)

Country Link
EP (1) EP1879597A2 (en)
JP (1) JP2008540510A (en)
KR (1) KR20080038085A (en)
CN (1) CN101262870A (en)
AU (1) AU2006290437A1 (en)
CA (1) CA2606727A1 (en)
WO (1) WO2007031879A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2554167T3 (en) * 2007-07-06 2015-12-16 Promedior Inc. Methods and compositions useful in the treatment of mucositis
CN102159950B (en) * 2008-06-13 2014-12-17 凯斯西部预备大学 Compostions and methods for treating corneal inflammation
US8367316B2 (en) 2009-05-01 2013-02-05 Alfagene Bioscience, Inc. Human gastrointestinal stem cell-derived primary intestinal epithelial cell system and methods of use thereof
CA2868458A1 (en) * 2012-03-28 2013-10-03 University Of Maryland, Baltimore Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections
CN107669692B (en) * 2017-09-07 2020-09-29 中国人民解放军第二军医大学 Application of MPLA in preparation of medicines for preventing and treating intestinal injury caused by ionizing radiation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013440A2 (en) * 2001-08-10 2003-02-20 Eisai Co., Ltd. Treatment and prevention of heat shock protein-associated diseases and conditions
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US20050215517A1 (en) * 1999-01-14 2005-09-29 Rossignol Daniel P Use of an anti-endotoxin drug in the prevention and treatment of disease
WO2003013440A2 (en) * 2001-08-10 2003-02-20 Eisai Co., Ltd. Treatment and prevention of heat shock protein-associated diseases and conditions
WO2003105861A1 (en) * 2002-06-13 2003-12-24 Eisai Co., Ltd. Use of an anti-endotoxin drug in the prevention and treatment of disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FORT MADELINE M ET AL: "A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease", JOURNAL OF IMMUNOLOGY, vol. 174, no. 10, May 2005 (2005-05-01), pages 6416 - 6423, XP002436852, ISSN: 0022-1767 *
SONIS S T: "A BIOLOGICAL APPROACH TO MUCOSITIS", JOURNAL OF SUPPORTIVE ONCOLOGY, BIOLINK COMMUNICATIONS,, US, vol. 2, no. 1, January 2004 (2004-01-01), pages 21 - 36, XP009053477, ISSN: 1544-6794 *

Also Published As

Publication number Publication date
WO2007031879A2 (en) 2007-03-22
JP2008540510A (en) 2008-11-20
EP1879597A2 (en) 2008-01-23
CA2606727A1 (en) 2007-03-22
AU2006290437A1 (en) 2007-03-22
KR20080038085A (en) 2008-05-02
CN101262870A (en) 2008-09-10

Similar Documents

Publication Publication Date Title
WO2006058236A3 (en) Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
WO2005082925A3 (en) Novel steroid agonist for fxr
WO2008057579A3 (en) Dosage forms and co-administration of an opioid agonist and an opioid antagonist
WO2007019439A3 (en) Block copolymer compositions and uses thereof
WO2006058059A3 (en) Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
IL184126A0 (en) Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release
MY153975A (en) Pyridine derivatives as s1p1/edg1 receptor modulators
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2009025876A8 (en) Crystalline forms of erlotinib hcl and formulations thereof
IL182090A (en) 2,6-substituted-4-monosubstituted amino-pyrimidines as prostaglandin d2 receptor antagonists
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
WO2007076260A3 (en) Farnesoid x receptor agonists
PL1740156T3 (en) Method for the production of an abuse-proof, solid form of administration
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
MY150736A (en) Mousse
WO2006138503A8 (en) New regimens for oral monophasic contraceptives
WO2008051564A3 (en) Crystalline forms of palonosetron hydrochloride
WO2009059143A3 (en) Use of toll-like receptor 4 antagonists for the treatment or prevention of osteoarthritic conditions
WO2007031879A3 (en) Lipid a analogs for treating oral and gastrointestinal mucositis
GB0500815D0 (en) Method for preparation of 10, 11-dihydro-10-hydroxy-5H-divenz/b,f/azepine-5-carboxamide
WO2007078271A3 (en) Lansoprazole orally disintegrating tablets
WO2007105223A3 (en) Methods of diagnosing pon1-hdl associated lipid disorders
WO2004071465A3 (en) Methods and kits for use in the diagnosis and treatment of endotoxemia
WO2007075980A3 (en) Lansoprazole orally disintegrating tablets
WO2007007182A3 (en) Solid and liquid dosage forms of an antiepileptic agent

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006290437

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006290437

Country of ref document: AU

Date of ref document: 20060515

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006290437

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2606727

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008510678

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200680016561.4

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006831669

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077028786

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWP Wipo information: published in national office

Ref document number: 2006831669

Country of ref document: EP